A Phase 1/2 study of the PD-L1 inhibitor, BGB-A333, alone and in combination with the PD-1 inhibitor, tislelizumab, in patients with advanced solid tumours

[1] Alsaab HO(2017)PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome Front Pharm 8 561-707

[2] Sau S(2017)Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade Oncotarget 8 110693-90

[3] Alzhrani R(2020)Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies J Immunother Cancer 8 e000404-8

[4] Tatiparti K(2019)The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors J Immunother Cancer 7 278-8

[5] Bhise K(2020)Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials Ther Adv Med Oncol 12 1758835920937612-24

[6] Kashaw SK(2018)The binding of an anti-PD-1 antibody to FcγRΙ has a profound impact on its biological functions Cancer Immunol Immunother 67 1079-95

[7] Bai J(2020)Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma J Immunother Cancer 8 e000341-89

[8] Gao Z(2019)Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001 Ann Oncol 30 582-22

[9] Li X(2018)Phase 1/2 study investigating safety, tolerability, pharmacokinetics, and preliminary antitumor activity of anti-PD-L1 monoclonal antibody BGB-A333 alone and in combination with anti-PD-1 monoclonal antibody tislelizumab in patients with advanced solid tumors J Clin Oncol 36 TPS3113-33

[10] Dong L(2010)B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance Blood 116 1291-47

[1] Alsaab HO(2017)PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome Front Pharm 8 561-707

[2] Sau S(2017)Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade Oncotarget 8 110693-90

[3] Alzhrani R(2020)Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies J Immunother Cancer 8 e000404-8

[4] Tatiparti K(2019)The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors J Immunother Cancer 7 278-8

[5] Bhise K(2020)Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials Ther Adv Med Oncol 12 1758835920937612-24

[6] Kashaw SK(2018)The binding of an anti-PD-1 antibody to FcγRΙ has a profound impact on its biological functions Cancer Immunol Immunother 67 1079-95

[7] Bai J(2020)Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma J Immunother Cancer 8 e000341-89

[8] Gao Z(2019)Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001 Ann Oncol 30 582-22

[9] Li X(2018)Phase 1/2 study investigating safety, tolerability, pharmacokinetics, and preliminary antitumor activity of anti-PD-L1 monoclonal antibody BGB-A333 alone and in combination with anti-PD-1 monoclonal antibody tislelizumab in patients with advanced solid tumors J Clin Oncol 36 TPS3113-33

[10] Dong L(2010)B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance Blood 116 1291-47